Wilson Sonsini Goodrich & Rosati advised LENZ Therapeutics on the transaction. LENZ Therapeutics (Nasdaq: LENZ), a late clinical-stage biopharmaceutical company, announced that it has entered into...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati is representing LENZ Therapeutics in the transaction, Goodwin Procter is representing Graphite Bio and Latham & Watkins is representing the placements...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati represented LENZ in the transaction. Biopharmaceutical company LENZ Therapeutics announced that it raised $83.5 million in an oversubscribed Series B financing....
You must be a Standard 1 Year member to access this content.
